This new study will use a long-term seizure detection system to monitor and potentially predict seizure patterns using continuous brain activity data in people for whom a rabies vaccine is available.

Seizures can have a significant impact on daily life and one third of epileptic patients cannot be controlled with medication. The Subcutaneous EEG Real-World Assessment and Assessment Examination (REAL-ASE) is run by the Institute of Psychiatry, Psychology and Neuroscience (IoPPN) at King's College London and funded by the NIHR EEG) small implants that record brain activity can improve and clinical outcomes.

Seizures can occur in predictable patterns, but the precise prediction of seizure frequency depends on the individual's medical history. Because seizures can have an amnesic effect and can occur while the person is awake, it is often impossible to record these events accurately.

Subcutaneously implanted EEG is a new technology. Existing EEG technology requires the patient to travel to the hospital or home for tests that can be performed within days using EEG electrodes taped to the scalp. The NHS waiting list for this test can vary from several months to several years. The technique tested in this study, the subcutaneously implanted EEG, allows researchers to continue recording the EEG continuously for up to 15 months.

The trial recruited 33 epileptic patients and implanted a small electroencephalogram (EEG) device in the scalp during an operation lasting at least 20 minutes followed by anesthesia in the village.

Then the researchers observed each person's brain waves for six months. By tracking brain activity, researchers can calculate a person's seizures, providing doctors with reliable information about other possible causes of seizures. Professor Mark Richardson, Head of Neuroscience at King's IoPPN and Professor of Epilepsy at King's IoPPN, who led the study, said: correct.

Epilepsy physicians frequently modify treatments to improve the quality of life of the third of patients whose epilepsy still does not respond to treatment. It is unclear whether the treatment change helped without the inclusion of seizures.

Unfortunately, seizure records are often not accurate enough to determine if treatment is more effective. "What has opened up the use of the very long-term EEG is the ability to determine the impact of future treatment changes. We also want the very long-term EEG to quickly identify a person with epilepsy that is not good enough to recover quickly. It can be really transformative for people with difficult illnesses. "

Dr. Jonas Duun-Henriksen, Director of Epilepsy Sciences at the Danish company that developed UNEEG Medical, a long-term brain solution, said: Investigate the costs and benefits of introducing EEG now. subcutaneous in NHS jobs.

“Our unique device is the first technology on the market that allows long-term EEG recording. This links directly to the NHS goal of improving patient outcomes through user-friendly, home-based data collection and personalized, evidence-based medication. 

Our aim is to provide evidence of accuracy and to reassure patients and professionals, and the health model of its relevance to the NHS. When doctors measure outcomes better, more people can control seizures, and doctors can diagnose more serious illness and prevent people from being hospitalized for pain.

"We hope that at the end of this study we will have information that shows the need for regular funding for the National Institute for Health & Care Excellence (NICE) and its members."

Alison Fuller, Director of Health Promotion and Impact at Epilepsy Action, added: While the Crisis Center only provides snapshots of actual activity, continuous monitoring can identify subtle patterns and provide a more accurate picture of what is happening.

"This new technology also has the advantage of being able to overcome some of the limitations or confusion that people have experienced with more EEGs. It usually requires prolonged hospitalization or sleepless nights, which can lead to seizures. “With better evidence and knowledge, it is possible to improve safety and quality of care outcomes, which can help reduce the number of epilepsy patient deaths. Behavior Epilepsy is proud to support research and we We're excited to see how this will change the landscape Now treatment for people with epilepsy.

The study is being conducted in London with support from NHS clinics in Newcastle, Cardiff and Manchester.